A randomized controlled trial of hysteroscopic lesion excision combined with LNG-IUS for symptomatic adenomyosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062505

Enrollment

Unknown

Registered

2022-08-10

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis

Interventions

combined group:Hysteroscopic lesion excision combined with LNG-IUS

LNG-IUS group :Intrauterine insertion of LNG-IUS

Eligibility

Sex/Gender

Female

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Age 30-50 years; 2. Subtype I, II, IV AM diagnosed by MRI, with dysmenorrhea or/and menorrhagia. 3. No fertility requirement and desire to preserve the uterus. 4. Signed informed consent and can comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1. Contraindication to surgery. 2. Uterine cavity depth of 10 cm or uterine size>12 weeks gestation. 3. Established pregnancy or breastfeeding. 4. Steroid hormone therapy was taken the 3 months before surgery. 5. Atypical hyperplasia of the endometrium. 6. Combined with congenital uterine malformation, such as unicorns uterus, septate uterus, or duplex uterus. 7. Combined cervical dysplasia, acute infection of the pelvis, or acute attack of chronic infection. 8. Suspected or known malignancy or combined benign lesions requiring hysterectomy. 9. History of previous AM lesion resection.

Design outcomes

Primary

Measure	Time frame
VAS of dysmenorrhea;PBAC of menorrhagia;	—

Secondary

Measure	Time frame
Uterine volume;Serum Ca125;Expulsion rate of LNG-IUS;	—

Countries

China

Contacts

Public ContactJian Zhang

The International Peace Maternity and Child Health Hospital

ipmch@foxmail.com+86 18017316017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026